Market Update: S&P/ASX200 Closes The Session in Red: What Market Participants Need to Know?

The Australian stock market closed the trading session in red on 29th November 2019. The benchmark index, i.e. S&P/ASX200 settled at 6846, declining by 18 points or 0.3% on an intraday basis. Let us now have a look at the performances of some sectors. S&P/ASX 200 Financials (Sector) stood at 6,074.3 after a decline of 27.5 points and S&P/ASX 200 Information Technology (Sector) ended the trading session at 1,474.2, reflecting a fall of 0.27%. All Ordinaries closed the trading session at 6948, demonstrating a fall of 17.6 points or 0.3% on an intraday basis.

However, there were some companies that managed to close their session in green and provided market players an opportunity to make some money. Virgin Money UK Plc (ASX: VUK) ended the session at a closing price of A$3.350 per share, with a rise of 24.535% on an intraday basis. Another performer of the session was Mayne Pharma Group Limited (ASX: MYX), with a share price of A$0.465, up 5.682% on 29th November 2019.

Readers are advised that they should have a glance at the information which have been covered by us. We have covered notable information on four fintech companies i.e. Z1P, EML, APT and FXL. To read, please click here.

Virgin Money UK Plc Reports Full Year Results

Virgin Money UK Plc (ASX: VUK), on 29th November 2019, announced its full year results for FY19 and stated that they represent strong performance in comparison to the current market. Front book lending pricing remains resilient, despite competitive pressures. The business deposit pricing continues to offer funding at rates which are beneficial to its overall Group funding. The net interest margin of the company stood at 1.66% and underlying profit reached to £539 million.

The company also stated that it is investing in its business and well-placed to continue its momentum after three years of consecutive growth, ensuring responsible lending as well as managing risk through the cycle.

Mayne Pharma Group Limited Up 5.682% on Australian Securities Exchange.

Mayne Pharma Group Limited (ASX: MYX) recently announced that Ron Best ceased to be a Director in the company from 22nd November 2019. Moreover, key personnel of the company addressed the shareholders and stated that, in FY19, Mayne reported revenue amounting to $525 million, reflecting a fall of 1% against pcp. The company posted a gross profit of $290 million, up 13% year-on-year with EBITDA amounting to $112 million, down 4% on pcp.

The net loss after tax for the period was impacted by intangible asset impairments in generic area. The impairment, which was disappointing, resets balance sheet and is expected to improve reported net profit and earnings per share (or eps) in the future period. However, net operating cash flow was an inflow amounting to $107 million enabling net debt to reduce in 2H by $18 million to $280 million.

VUK Daily Technical Chart (Source: Thomson Reuters)

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK